Adding cetuximab to 5FU/RT therapy, the authors observed increased PDX and PDO sensitivity with wild-type KRAS compared to the mutated KRAS. Another study carried out by Vlachogiannis et al., through NSG analysis, revealed an overlapping of 96% of the mutational spectrum between PDOs and their parental tumor [63]. The gene discussed is KRAS; the disease is neoplasm.